Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I guess you have never seen bio techs go from $5 to $100 overnight. You may want to explore that history just a bit.
Based on your theory Anavex is on its last legs. This would be the optimum time to short it. Obviously some institutions agree, there is a 22,000,000 sh short position.
Have the courage of your convictions. Short Anavex like the big dogs are. You are a big dog, right?
That scenario would be the best outcome for BP. Not so much for Anavex shareholders.
OK. Somebody has to be the Grinch. 😞
Hang around and we will see how this turns out. Approval in the EU changes everything. No approval and you might be right.
You could short this if you are that convinced Anavex is going to penny land. $3.75 a share would be a nice profit.
OK. You win. $400 a share it is. 😉
First of all I didn't accuse you of braking any laws. Indirectly I accused you of wasting people's time which you do with great frequency.
As far as my cost basis, I am a relatively newcomer to NWBO so my cost basis is just fine. Thanks for being concerned.
7 months isn't up yet.
A buyout would be fine...@ $100/sh.
Speaking of things that don't work....
Your id was created 12/26/23. That was 128 days ago. You have made 2190 posts in those 128 days. That works out to slightly over 17 posts a day.
Posts worth reading in that 128 days, zero.
Resistance may be futile but bullshit is inevitable.
Apparently bringing information to this board is not without controversy.
I would have thought that the similarities i.e. using tumor tissues would be considered a bit of validation for NWBO approach.
Toutain had been with the company since 2018.
Looks like he left for a significant increase in pay.
"Us" ????
That page lists all the presentations and conferences that Anavex has done.
You probably should go to this web page and survey the contents.
https://www.anavex.com/newsroom
One just smiles and nods at the village idiot as you walk by.
Another similar approach to GBM. Several years behind. NWBO is plowing the ground.
https://medicalxpress.com/news/2024-05-mrna-cancer-vaccine-triggers-fierce.html
No real reason to start that full court process yet. Anavex has been doing some of that already by presenting at the various health conferences and investor conferences. Those areas target the KOLs directly.
There is a significant amount of time before the first approval can arrive. Which means bringing that sort of skill set on board too early is a waste of resources.
As another poster commented, those skills may come with a partnership rather than needing to be in house.
But hey, it's something to bad mouth the company over so let's not forget that.
Surprisingly enough the chart for AVXL in the last 2 hours of trading mirrored XBI in shape.
Interesting that a developmental stock like AVXL should respond so strongly to interest rate news.
That couldn't be algorithms in action could it?
Does that include doing an offering through a big brokerage house?
I suggest you are using the term blinded in a way that is not its usual meaning.
As I read read your post I understand that what you mean is the company doesn't have the end of trial data to compare with the intake data at taken at the beginning of the OLE and therefore can not evaluate the intake data at this time.
Blinded generally is understood to mean that the data being taken by the CRO is not made available to the company until the end of the trial and that includes interim data from multiple sequential measures.
A minor quibble about word usage.
According to what I read the EMA considered Covid an emergency and so far nothing else.
The FDA has a rolling submission process for drug granted Fast Track designation. So far Anavex has not applied for Fast Track or Priority Review for AD.
The EMU utilizes rolling submission only in emergency health situations.
News would be great. Approvals are essential. News has a short shelf life. Approvals make the company.
I get that the SP sucks. I chose to pay off my margin. Not what I wanted to do. That was better than selling shares at these prices.
Really? That's the best you got?
You do realize that he was asked for his opinion and gave it.
The rest of your rant was your opinion based on nothing.
EMU application process is in motion.
Nothing new on the FDA front.
They can be fatal. Placebo effects can be positive or negative. The negative is easier to demonstrate.
https://en.wikipedia.org/wiki/Voodoo_death.
There was a case presented in one of my classes of man in WWII from one of the Caribbean islands where voodoo was practiced. The man was stationed in Asia in the British army. He received a letter saying that he had a death curse placed on him by a voodoo priest and that he would die on a particular time and day a few weeks in the future. The medical people tried to explain to him that it wasn't possible for a curse to kill him and he would be fine. He did not believe them. On the day in question he became very nervous and went to the medical people. They monitored him and tried to reassure him that he would be OK. As the appointed time approached his blood pressure started dropping and he died at the appointed time.
That is the negative side of the placebo effect, there have been examples of the positive side that are also very strong.
Wow, you can read AD tweets.
The placebo side effects are just as real as the effects.
Speak for yourself.
So far most of the time when he releases news the share price drops. So why do you think that releasing more news is going to change that pattern?
Your insights are invaluable.
It's biotech. It always has had significant risk.
Contrary to popular whining, I think the overall level of risk has been reduced considerably.
Alas, it's not done till it's done.
Thanks for the clarification.
Any relationship between your post and reality is an unusual occurrence.
How do you know that they are getting rapporteur comments in early March?
I must have missed that.
Where did you find the information that the company filed it's LOI in mid December?
Got it. That is more of the techniques of the shorts. Whether that has been coded into algorithms I do not know.
TA looks for patterns. Those patterns are found in human behavior.
AI is better at discovering patterns than Human TA. It works from much larger data sets with much finer granularity.
However, many of the HFT programs rely on microsecond pattern recognition and front running based on data distribution delays. That is for the high activity stocks with large volumes of trades.
You can see the computer programs at work if you have LVL II. Put in a bid and watch the LVL II step away from your bid instantaneously on a slow day.
Cancel your bid and the bid and ask move down instantaneously.
Anavex chart follows the XBI chart in shape much of the time with a 1.5 to 2 beta in both directions. There is no real reason for that behavior except for algo trading.